Clinical Trial Update: Comparison of Cardiovascular Outcomes of Pioglitazone and Metformin in Type 2 Diabetes Patients [Phase 4]

View source ↗

Summary

A Phase 4 trial comparing cardiovascular outcomes of pioglitazone and metformin in type 2 diabetes has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• PIOGLITAZONE (Pioglitazone)
• metformin (metformin)

Snippet

Sponsor: Post Graduate Institute of Medical Education and Research, Chandigarh | Conditions: Type 2 Diabetes | Phase 4 | Status: WITHDRAWN